26EHSPMCLMCTSBINDRBTRFA: RFA Fee-for-Service Claims for Continuous Subcutaneous Insulin Devices

The Massachusetts Executive Office of Health and Human Services (EOHHS) is seeking rebate agreements with manufacturers of continuous subcutaneous insulin devices, specifically tubeless products, to ensure ongoing access for MassHealth members and Health Safety Net patients following the expiration of existing rebate arrangements. The procurement, identified by solicitation number BD-26-1039-EHS01-ASHWA-120511, involves establishing preferred product status through fixed Guaranteed Net Unit Prices (GNUP) per National Drug Code (NDC) for products dispensed via pharmacy fee-for-service and managed care systems across Massachusetts. The initial contract term spans 24 months starting January 1, 2026, with the possibility of extensions up to three additional years. Manufacturers must submit a comprehensive rebate proposal, including a completed State Rebate Agreement, Attachment A detailing rebate offers per NDC, and a cover letter outlining strategies for smooth patient transitions, customer service, and training. The evaluation process emphasizes a best value approach, considering rebate competitiveness, experience, transition plans, and responsiveness, with no reliance solely on price. The agreement incorporates standard contractual provisions such as entire agreement, governing law under Massachusetts statutes, and rights to modify or terminate with appropriate notice, but does not reference federal FAR clauses or standard federal contract forms. Administrative details specify that rebates are invoiced quarterly, with payments due within 38 days, and that record-keeping and audits are subject to state and federal laws. The contract emphasizes compliance, confidentiality, and the manufacturer’s obligation to provide dedicated customer support. Delivery performance is based on actual dispensing, with the contract running from January 2026 through December 2027, and includes provisions for amendments, conflict of interest clauses, and dispute resolution. Submission instructions require proposals to be sent by October 3, 2025, via email or mail, including a signed cover letter certifying the response’s validity and detailing the manufacturer’s transition strategy, experience, and contact information, with no specified page or word limits.